NGNE

Neurogene Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website neurogene.com
Employees(FY) 82
ISIN US64135M1053

Performance

+0.3%

1W

-5.37%

1M

+13.07%

3M

+153.12%

6M

+71.88%

YTD

+91.46%

1Y

Profile

Neurogene Inc. develops life-changing genetic medicines for patients and their families affected by neurological diseases. Its product candidate includes NGN-401, an investigational AAV9 gene therapy for the treatment of Rett syndrome; and NGN-101 to treat neuronal ceroid lipofuscinosis subtype 5 batten disease. The company is headquartered in New York, New York.

Advanced Technical Analysis

Technical Analysis of NGNE 2024-05-10

Overview:

In analyzing the technical indicators for NGNE over the last 5 days, we will delve into the trend, momentum, volatility, and volume indicators to provide a comprehensive outlook on the possible stock price movement in the coming days. By examining these key indicators, we aim to offer valuable insights and predictions for informed deci...

See more ...

Recent News & Updates

2024-05-10 01:54
NGNE Stock Earnings: Neurogene Beats EPS for Q1 2024(Investorplace)
2024-05-09 19:30
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates(Businesswire)
2024-05-09 19:30
Neurogene Reports First Quarter 2024 Financial Results and Highlights Recent Updates(Businesswire)
2024-05-06 18:19
Neurogene Presents Favorable Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome during ASGCT Annual Meeting(Businesswire)
2024-04-22 16:36
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting(Business Wire)
2024-04-22 04:36
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting(Businesswire)
2024-03-20 05:31
Neurogene Inc (NGNE) Reports Financial Results for Q4 and Full Year 2023(GuruFocus.com)
2024-03-19 06:48
With 32% ownership, Neurogene Inc. (NASDAQ:NGNE) has piqued the interest of institutional investors(Simply Wall St.)
2024-03-18 16:14
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates(Business Wire)
2024-03-18 04:14
Neurogene Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Updates(Businesswire)
2024-03-04 07:30
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial(Business Wire)
2024-03-03 18:30
Neurogene Announces Expansion and Plans for More Rapid Patient Enrollment of Rett Syndrome Gene Therapy Clinical Trial(Businesswire)
2024-02-29 07:30
Neurogene to Participate in Upcoming Investor Conferences(Business Wire)
2024-02-28 18:30
Neurogene to Participate in Upcoming Investor Conferences(Businesswire)
2024-01-16 07:00
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer(Business Wire)
2024-01-15 18:00
Neurogene Announces Appointment of Julie Jordan, M.D., as Chief Medical Officer(Businesswire)
2024-01-05 07:00
Neurogene Announces Business Update and 2024 Outlook(Business Wire)
2024-01-04 18:00
Neurogene Announces Business Update and 2024 Outlook(Businesswire)
2023-12-19 07:00
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million(Business Wire)
2023-12-18 18:00
Neurogene Announces Closing of Merger with Neoleukin Therapeutics and Concurrent Private Placement of $95 Million(Businesswire)

Page 1 of 1

previousnext